Company: AEMD
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001683168-25-006049
Chunk: 43

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-13
Form: 10-Q
Item: Item 8
Chunk 43
---
 value since the closing price on that date of $1.20 per share was below the weighted average exercise price of our outstanding
stock options.

At June 30, 2025, there was approximately $206,106
of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted average period of
.71 years.

9. WARRANTS

We did not issue any warrants in the three-months
ended June 30, 2025. We issued 2,065,500 warrants in connection with the May 17, 2024 public offering during three-months ended June 2024.

A summary of warrant activity during the three months
ended June 30, 2025 is presented below:

    Schedule of warrant activity

    Amount

    Range of
Exercise
Price

    Weighted
Average
Exercise
Price

    Warrants outstanding at March 31, 2025

    2,357,124

    $
    2.99 – 4.64

    $
    3.55

    Granted

    –

    –

    –

    Exercised

    –

    $
    –

    $
    –

    Cancelled/Expired

    (227,937
    ) 
     
    $
    4.64

    $
    4.64

    Warrants outstanding at June 30, 2025

    2,129,187

    $
    2.99 – 4.64

    $
    3.44 

    Warrants exercisable at June 30, 2025

    2,129,187

    $
    2.99 – 4.64

    $
    3.44

10. COMMITMENTS AND CONTINGENCIES

LEASE COMMITMENTS

Office, Lab and Manufacturing Space Leases

In December 2020, we entered into an agreement to
lease approximately 2,823 square feet of office space and 1,807 square feet of laboratory space located at 11555 Sorrento Valley Road,
Suite 203, San Diego, California 92121 and 11575 Sorrento Valley Road, Suite 200, San Diego, California 92121, respectively. The agreement
carries a term of 63 months and we took possession of the office space effective October 1, 2021. We took possession of the laboratory
space effective January 1, 2022. In